Following its FDA approval, Leqembi is expected to make $12.9bn in sales

After receiving FDA approval in January 2023, Biogen/Eisai’s new Alzheimer’s disease Leqembi (lecanemab) is expected to become a blockbuster, with a predicted $12.9bn predicted to be made in sales between 2023 and 2028. The drug is still awaiting approval in the EU and Japan, with these approvals potentially making it the top-selling Alzheimer’s drug.

The monoclonal antibody targets amyloid beta A4 protein, selectively binding and eliminating amyloid beta plaques, which is thought to be significant for treating Alzheimer’s disease. The FDA’s approval of this drug followed data from the phase 2 Athena AD trial, which showed a significant reduction in the number of amyloid beta plaques in the brain as well as showing a statistically significant reduction in cognitive decline in patients treated with Leqembi compared to those on a placebo dose.

It is expected that the drug’s biggest market will be in the US, with this region expected to contribute $7.7bn of the 2023-2028 forecasted sales. The anticipated further approvals are also expected to contribute to revenue growth.

In a press release published last week, Michael Irizarry MD, deputy chief clinical officer and senior vice president of clinical research at Eisai Inc, commented: “Our latest research examines the real-world outcomes based on lecanemab’s impact on clinical results and safety, including its effect on health-related quality of life. Through our ongoing research, we hope to help simplify the patient journey and improve the lives of those living with Alzheimer’s disease.”